Chakkapong Burudpakdee
A5089188949- Acute Lymphoblastic Leukemia research
- Kawasaki Disease and Coronary Complications
- Neuroblastoma Research and Treatments
- COVID-19 Clinical Research Studies
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Impact on Reproduction
- T-cell and B-cell Immunology
- Long-Term Effects of COVID-19
- Lung Cancer Research Studies
- Graphene and Nanomaterials Applications
- Vasculitis and related conditions
- Heat shock proteins research
- Genetic Neurodegenerative Diseases
- Complement system in diseases
- Hedgehog Signaling Pathway Studies
- Inflammasome and immune disorders
- Integrated Circuits and Semiconductor Failure Analysis
- Genetics and Neurodevelopmental Disorders
- Systemic Lupus Erythematosus Research
- Glioma Diagnosis and Treatment
- Autoimmune and Inflammatory Disorders Research
- Cancer therapeutics and mechanisms
- Fungal and yeast genetics research
Temple University Health System
2024
Fox Chase Cancer Center
2024
University of Pennsylvania
2020-2022
Philadelphia University
2020-2022
Children's Hospital of Philadelphia
2020-2022
Pace University
2019
BACKGROUND. Initial reports from the severe acute respiratory coronavirus 2 (SARS–CoV-2) pandemic described children as being less susceptible to disease 2019 (COVID-19) than adults. Subsequently, a and novel pediatric disorder termed multisystem inflammatory syndrome in (MIS-C) emerged. We report on unique hematologic immunologic parameters that distinguish between COVID-19 MIS-C provide insight into pathophysiology.
Pediatric COVID-19 following SARS-CoV-2 infection is associated with fewer hospitalizations and often milder disease than in adults. A subset of children, however, present Multisystem Inflammatory Syndrome Children (MIS-C) that can lead to vascular complications shock, but rarely death. The immune features MIS-C compared pediatric or adult remain poorly understood. We analyzed peripheral blood responses hospitalized infected patients (pediatric COVID-19) MIS-C. had patterns T cell-biased...
Abstract Most children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have mild or minimal disease, a small proportion developing disease multisystem inflammatory in (MIS-C). Complement-mediated thrombotic microangiopathy (TMA) has been associated SARS-CoV-2 adults but not studied the pediatric population. We hypothesized that complement activation plays an important role and sought to understand if TMA was present these patients. enrolled 50 hospitalized...
Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) infection pediatric patients. Weeks after an often mild or asymptomatic initial with SARS-CoV-2 children may present severe shock-like picture and marked inflammation. MIS-C varying degrees cardiovascular hyperinflammatory symptoms. Here we perform comprehensive analysis the plasma proteome more than 1400 proteins SARS-CoV-2. We hypothesize that would reflect...
To study the biology and identify markers of severe cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity (ICANS) in children after chimeric antigen receptor T-cell (CAR T) treatment.We used comprehensive proteomic profiling to measure over 1,400 serum proteins at multiple serial timepoints a cohort patients with B-cell acute lymphoblastic leukemia treated CD19-targeted CAR T CTL019 on two clinical trials.We identified fms-like tyrosine kinase 3 (FLT3) mast cell...
Abstract Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibody responses in children remain poorly characterized. Here, we show that pediatric patients with multisystem inflammatory syndrome (MIS-C) possess higher SARS-CoV-2 spike immunoglobulin G (IgG) titers compared those severe coronavirus disease 2019, likely reflecting a longer time since the onset of infection MIS-C patients.
Inclusions of disordered protein are a characteristic feature most neurodegenerative diseases, including Huntington’s disease. disease is caused by expansion polyglutamine tract in the huntingtin protein; mutant (mHtt) unstable and accumulates large intracellular inclusions both affected individuals when expressed eukaryotic cells. Using mHtt-GFP Saccharomyces cerevisiae , we find that dynamic, mobile, gel-like structures concentrate mHtt together with disaggregase Hsp104. Although may...
ABSTRACT Pediatric COVID-19 following SARS-CoV-2 infection is associated with fewer hospitalizations and often milder disease than in adults. A subset of children, however, present Multisystem Inflammatory Syndrome Children (MIS-C) that can lead to vascular complications shock, but rarely death. The immune features MIS-C compared pediatric or adult remain poorly understood. We analyzed peripheral blood responses hospitalized infected patients (pediatric COVID-19) MIS-C. had patterns T...
ABSTRACT SARS-CoV-2 antibody responses in children remain poorly characterized. Here, we show that pediatric patients with multisystem inflammatory syndrome (MIS-C) possess higher spike IgG titers compared to those severe coronavirus disease 2019 (COVID-19), likely reflecting a longer time since onset of infection MIS-C patients.
Neuroblastoma is a commonly lethal solid tumor of childhood and intensive chemoradiotherapy treatment cures ~50% children with high-risk disease. The addition immunotherapy using dinutuximab, monoclonal antibody directed against the GD2 disialoganglioside expressed on neuroblasts, improves survival when incorporated into front-line therapy shows robust activity in regressing relapsed disease combined chemotherapy. Still, many succumb to neuroblastoma progression despite receiving...
Invariant natural killer T (iNKT) cells comprise a unique subset of lymphocytes that are primed for activation and possess innate NK-like functional features. Currently, iNKT cell-based immunotherapies remain in early clinical stages, little is known about the ability these to survive retain effector functions within solid tumor microenvironment (TME) long-term. In conventional (T CONV ), cellular metabolism linked their adapt nutrient-poor TME. contrast, bioenergetic requirements –...
Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of the Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) pandemic pediatric patients. Weeks after an often mild or asymptomatic initial infection with SARS-CoV-2 children may present severe shock-like picture and marked inflammation. MIS-C varying degrees cardiovascular hyperinflammatory symptoms. We performed comprehensive analysis plasma proteome more than 1400 proteins SARS-CoV-2. hypothesized that would...
<div>AbstractPurpose:<p>To study the biology and identify markers of severe cytokine release syndrome (CRS) immune effector cell–associated neurotoxicity (ICANS) in children after chimeric antigen receptor T-cell (CAR T) treatment.</p>Experimental Design:<p>We used comprehensive proteomic profiling to measure over 1,400 serum proteins at multiple serial timepoints a cohort patients with B-cell acute lymphoblastic leukemia treated CD19-targeted CAR T CTL019 on two...
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Patients with B-Cell ALL Receiving CAR T19
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Patients with B-Cell ALL Receiving CAR T19
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Patients with B-Cell ALL Receiving CAR T19
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Patients with B-Cell ALL Receiving CAR T19
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Patients with B-Cell ALL Receiving CAR T19
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Patients with B-Cell ALL Receiving CAR T19
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Patients with B-Cell ALL Receiving CAR T19
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Patients with B-Cell ALL Receiving CAR T19
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Patients with B-Cell ALL Receiving CAR T19
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Patients with B-Cell ALL Receiving CAR T19